BridgeBio Pharma BBIO

Kumar Haldea Revocable Trust U/A DTD 12/19/2018 (Director) plans to sell 120,000 BBIO shares, about $6.5M

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Oct 8, 2025
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Conversion Management Incentive Units
  4. 10b5-1 plan adopted: Mar 31, 2025

All of Kumar Haldea Revocable Trust U/A DTD 12/19/2018's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 11,294 shares at $55.09 on Oct 8, 2025 · Form 4
  • Sold 8,705 shares at $54.39 on Oct 8, 2025 · Form 4
  • Sold 11,295 shares at $55.09 on Oct 8, 2025 · Form 4
  • Sold 20,000 shares at $54.8 on Oct 9, 2025 · Form 4
  • Sold 20,000 shares at $54.8 on Oct 9, 2025 · Form 4
  • Sold 12,576 shares at $62.91 on Nov 6, 2025 · Form 4
  • Sold 7,324 shares at $63.55 on Nov 6, 2025 · Form 4
  • Sold 12,529 shares at $62.91 on Nov 6, 2025 · Form 4
  • Sold 7,371 shares at $63.56 on Nov 6, 2025 · Form 4
  • Sold 7,308 shares at $61.87 on Nov 7, 2025 · Form 4
  • Sold 2,100 shares at $73.16 on Dec 4, 2025 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Get an email when BridgeBio Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

Data on this page was fetched . The filing on SEC.gov is the record.